• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Director Caballero Ruben was granted 43,605 shares, increasing direct ownership by 816% to 48,952 units (SEC Form 4)

    5/13/25 4:30:14 PM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $MOVE alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Caballero Ruben

    (Last) (First) (Middle)
    C/O MOVANO, INC.
    6800 KOLL CENTER PARKWAY

    (Street)
    PLEASANTON CA 94566

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Movano Inc. [ MOVE ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    05/09/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 05/09/2025 A 43,605(1) A $0 48,952 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. The reported transaction involved the reporting person's receipt of a grant of 43,605 restricted stock units ("RSUs") under the Company's Omnibus Incentive Plan in lieu of directors' fees for the period October 1, 2024 to June 30, 2025. The total reported in Column 5 includes the 43,605 newly awarded RSUs and 5,347 shares of common stock.
    /s/ Ruben Caballero by Mark R. Busch, attorney-in-fact 05/12/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $MOVE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MOVE

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $MOVE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Movano Health Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Quarterly Report on Form 10-Q

      PLEASANTON, Calif., May 23, 2025 /PRNewswire/ -- Movano Health (Nasdaq: MOVE)(the "Company") announced today that it received a notice (the "Notice") from the Listing Qualifications Department of the Nasdaq Stock Market ("Nasdaq") indicating that because the Company had not yet filed its Form 10-Q for the quarterly period ended March 31, 2025 (the "Form 10-Q"), the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) (the "Listing Rule") requiring Nasdaq-listed companies to timely file all periodic financial reports with the Securities and Exchange Commission (the "SEC"). The Form 10-Q was due on May 15, 2025.

      5/23/25 4:05:00 PM ET
      $MOVE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Movano Health's Board of Directors Initiates Process to Maximize Shareholder Value

      PLEASANTON, Calif., May 16, 2025 /PRNewswire/ -- Movano Health (NASDAQ:MOVE), a pioneer in health technology, announced today that its Board of Directors has initiated a process to explore strategic alternatives, including a sale, merger or similar transaction involving the Company, to maximize shareholder value.  To support this process, Movano Health's Board of Directors has engaged Aquilo Partners as its financial advisor and K&L Gates LLP as its legal counsel. There can be no assurance that this process will result in any transaction or other strategic change or as to the

      5/16/25 4:30:00 PM ET
      $MOVE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Movano Health's Proprietary Cuffless Blood Pressure Device Once Again Achieves Accuracy Commensurate with the FDA's Requirements

      Leveraging the Company's System-on-a-Chip (SoC), the clinical study results are another significant step forward in commercializing a cuffless, radio frequency (RF)-enabled blood pressure device PLEASANTON, Calif., April 22, 2025 /PRNewswire/ -- Movano Health (NASDAQ:MOVE), a pioneer in health technology, today announced positive results of its most recent 81-participant blood pressure clinical study. Movano Health's prototype demonstrated a level of accuracy well within the standards recognized by the FDA for blood pressure monitoring devices, achieving an overall mean absolute difference (MAD) of 4.9 mmHg, which significantly exceeds the 7 mmHg MAD threshold required per a standard for wea

      4/22/25 8:00:00 AM ET
      $MOVE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $MOVE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Caballero Ruben bought 22,000 shares, increasing direct ownership by 38% to 80,200 units (SEC Form 4)

      4 - Movano Inc. (0001734750) (Issuer)

      4/12/24 4:30:19 PM ET
      $MOVE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Fairbairn Emily bought 4,690,000 shares (SEC Form 4)

      4 - Movano Inc. (0001734750) (Issuer)

      4/4/24 5:30:08 PM ET
      $MOVE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Cogan Jeremy bought 45,000 shares, increasing direct ownership by 6% to 780,649 units (SEC Form 4)

      4 - Movano Inc. (0001734750) (Issuer)

      4/4/24 5:30:14 PM ET
      $MOVE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $MOVE
    SEC Filings

    See more
    • Movano Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Movano Inc. (0001734750) (Filer)

      5/23/25 4:05:24 PM ET
      $MOVE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form NT 10-Q filed by Movano Inc.

      NT 10-Q - Movano Inc. (0001734750) (Filer)

      5/21/25 5:22:02 PM ET
      $MOVE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Movano Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events

      8-K - Movano Inc. (0001734750) (Filer)

      5/19/25 8:48:13 AM ET
      $MOVE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $MOVE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Movano Inc.

      SC 13G - Movano Inc. (0001734750) (Subject)

      4/10/24 4:39:12 PM ET
      $MOVE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G/A filed by Movano Inc. (Amendment)

      SC 13G/A - Movano Inc. (0001734750) (Subject)

      4/9/24 5:41:12 PM ET
      $MOVE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G filed by Movano Inc.

      SC 13G - Movano Inc. (0001734750) (Subject)

      2/4/22 4:20:05 PM ET
      $MOVE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $MOVE
    Financials

    Live finance-specific insights

    See more
    • Movano Health Reports Q3 2024 Financial Results and Provides Business Update

      Highlights successful Evie Ring back-in-stock execution Updates status of EvieMED 510(k) application review Focuses on launch of EvieMED and securing B2B opportunities Conference Call at 2:00 PM PT/ 5:00 PM ET Today PLEASANTON, Calif., Nov. 14, 2024 /PRNewswire/ -- Movano Health (NASDAQ:MOVE), a pioneer in health technology, reported third quarter 2024 results and provided a business update. The Company continues to remain focused on three key business initiatives. Successful execution of the Evie Ring direct-to-consumer business (D2C) following the September 17th back-in-sto

      11/14/24 4:05:00 PM ET
      $MOVE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Movano Health Reports Q2 2024 Financial Results and Provides Business Update

      Prepares for September 17, 2024, Evie Ring back in stock dateAnnounces brand partnership with digital creator Heidi D'AmelioFocuses on launch of EvieMED and securing B2B opportunitiesConference Call at 2:00 PM PT/ 5:00 PM ET Today PLEASANTON, Calif., Aug. 14, 2024 /PRNewswire/ -- Movano Health (NASDAQ:MOVE), a pioneer in health technology, reported second quarter 2024 results and provided a business update. Following the successful close of the Company's April 2024 $24.1 million private placement that included a seed investment from a tier 1 multi-billion dollar medical device

      8/14/24 4:05:00 PM ET
      $MOVE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Movano Health Provides Progress Update on EvieMED Regulatory Filing

      Company continues to work with FDA to bring this pioneering healthcare product to market PLEASANTON, Calif., Aug. 5, 2024 /PRNewswire/ -- Movano Health (Nasdaq: MOVE) plans to meet with the FDA in mid-August, as part of the Company's ongoing process to secure a 510(k) clearance for the EvieMED Ring, a wearable designed to not only provide medical device functionality through its pulse oximetry feature, but also offer numerous wellness metrics related to sleep, activity and mood/energy/symptom logging. On April 21, 2024, Movano Health filed an updated 510(k) for the EvieMED Ring's pulse oximetry feature. At the time of the filing and based on prior interactions with the agency and its protoco

      8/5/24 9:00:00 AM ET
      $MOVE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $MOVE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Caballero Ruben was granted 43,605 shares, increasing direct ownership by 816% to 48,952 units (SEC Form 4)

      4 - Movano Inc. (0001734750) (Issuer)

      5/13/25 4:30:14 PM ET
      $MOVE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • CFO Cogan Jeremy was granted 62,986 shares, increasing direct ownership by 121% to 115,028 units (SEC Form 4)

      4 - Movano Inc. (0001734750) (Issuer)

      5/13/25 4:30:12 PM ET
      $MOVE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Chief Executive Officer Mastrototaro John was granted 77,521 shares, increasing direct ownership by 399% to 96,964 units (SEC Form 4)

      4 - Movano Inc. (0001734750) (Issuer)

      5/13/25 4:30:12 PM ET
      $MOVE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care